Artificial intelligence-assisted development and advancement of imaging markers of microvascular pathology for early diagnosis and prognosis prediction of cognitive impairment and dementia

Konkuk University Medical Center0 个研究点目标入组 91 人开始时间: 待定最近更新: 2023年8月21日

适应症

试验速览

暂无简介。

•An individual who has completed all planned research visits by participating in one of the preceding studies (IRB No. 0114-01-300(CRIS Registration number KCT0003181), IRB No. 0114-01-180(CRIS Registration number KCT0008510)).
•Age between 45 to 90 years old.
•Individuals who have agreed to participate in the clinical trial and have voluntarily signed the written informed consent form.
•Patients who meet one of the following diagnostic criteria:
•: Those who meet the diagnostic criteria for clinically normal, subjective, or mild cognitive impairment (based on NIA-AA 2011).
•: Those who meet the diagnostic criteria for clinically early Alzheimer's dementia (based on NIA-AA 2011).
•Patients who scored 1.0 on the CDR (Clinical Dementia Rating) at baseline in previous studies.
•Patients who scored 18 or higher on the MMSE and were mentally intact at baseline in previous studies.
•Patients presenting with any contraindications to MRI examinations.
•Patients presenting with any contraindications to MRI contrast medium:
•: Gadovist (Renal failure) - Estimated Glomerular Filtration Rate (eGFR) <30 mL / min.

•Those who did not participate in the previous studies (IRB No. 0114-01-300 (CRIS Registration number KCT0003181), IRB No. 0114-01-180 (CRIS Registration number KCT0008510)).
•Individuals who have not completed all planned research visits in the preceding studies.
•Patients presenting with any contraindication to MRI examination (e.g., history of brain surgery, presence of pacemakers, implanted metal devices, claustrophobia, or extensive tattoos).
•Patients presenting with any contraindication to the MRI contrast medium, such as Gadovist, in cases of renal failure (estimated glomerular filtration rate, eGFR, less than 30 mL/min).

发起方